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Research letter
Goblet cell scarcity and conjunctival
inflammation during treatment with dupilumab
in patients with atopic dermatitis
DOI: 10.1111/bjd.17538
DEAR EDITOR, Higher rates of conjunctivitis have been reported in
patients with atopic dermatitis (AD) treated with dupilumab, an
anti-interleukin (IL)-4Ra antibody inhibiting IL-4 and IL-13,
vs. patients treated with placebo.1 However, the exact pathome-
chanism has not been clarified. Given the necessity for optimal
treatment and risk management, the aim of this study was to
describe the histopathological characteristics of conjunctivitis
during dupilumab treatment in patients with AD.
Participants, selected from the BioDay registry, consisted of
74 patients with moderate-to-severe AD treated with dupilu-
mab for at least 16 weeks. Of these, 23% developed ophthal-
mologist-confirmed conjunctivitis requiring anti-inflammatory
treatment. We sequentially included six patients [three male;
median age 39 years, interquartile range (IQR) 29–54] in
whom a diagnostic conjunctival biopsy of the inferior fornix
was performed before initiation of ocular anti-inflammatory
treatment. Biopsies were fixed, paraffin-embedded and stained
with haematoxylin and eosin for histological assessment, and
additionally with CD3/CD4 [T helper (Th) cells] and Alcian
blue [mucus-containing goblet cells (GCs)]. Conjunctival
biopsies of two healthy controls were included. Biopsies were
assessed by two independent experienced pathologists. This
study did not fall under the scope of the Medical Research
Involving Human Subjects Act, confirmed by the local Medical
Research Ethics Committee (METC 18/537).
The most prominent histopathological feature in conjuncti-
val biopsies from patients with AD developing conjunctivitis
during dupilumab treatment was a scarcity of intraepithelial
GCs. Median GC density was 33 cells mm1 (IQR 11–49)
(Fig. 1a, b) in patients with AD with conjunctivitis vs. 283
and 363 cells mm1 in the two control samples. Five patients
showed a multicellular immune-cell stromal infiltrate, consist-
ing mainly of T cells (CD3+/CD4+) and eosinophils (Fig. 1c),
partially migrating into the conjunctival epithelium.
Conjunctival GCs are specialized mucus-secreting cells, vital
for ocular surface function.2 In healthy individuals lower for-
niceal GC counts vary between 88 and 30 cells mm1.3 All
patients included in our study had a decreased GC count (me-
dian 33 cells mm1) vs. controls (mean 323 cells mm1).
Mice studies have demonstrated that ocular IL-13 expression
normally stimulates GC proliferation and mucus secretion.4 By
blocking IL-13, dupilumab treatment may lead to GC hypopla-
sia, as IL-4Ra is expressed on conjunctival epithelium. This
might result in decreased mucin production, subsequent tear
film instability and mucosal epithelial barrier dysfunction,
leading to conjunctival inflammation in a subpopulation of
(predisposed) patients with AD. Clinically, the loss of GC-pro-
duced factors may result in dry eyes, as was reported by all
patients, and subsequently irritative conjunctivitis. As in this
study biopsies were performed after initiation of dupilumab,
GC scarcity might already be present before dupilumab treat-
ment, although patients did not experience ocular symptoms




Fig 1. Alcian blue-stained histological sections of the inferior bulbar
conjunctiva under light microscopy shows the presence of decreased
goblet-cell density in patients with AD treated with dupilumab
(original magnification 9 40). (a) Regions with no goblet cells (GCs)
interspersed with smaller regions of normal GC density. (b) In patient
6 no GC was found in the conjunctival biopsy. (c) Haematoxylin and
eosin stained histological sections of the inferior bulbar conjunctiva
under light microscopy show the presence of a superficial
inflammatory multicellular infiltrate in the conjunctival stroma
consisting of mainly T cells and eosinophils, partially migrating into
the conjunctival epithelium.
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Our histopathological findings do not correspond with the
histopathology of atopic keratoconjunctivitis and allergic con-
junctivitis, which is associated with an increased GC density and
increased mucus production, probably due to IL-13
overexpression.5,6 Dupilumab treatment might theoretically be
beneficial in these typical Th2-mediated ocular surface diseases.
It has been proposed that dupilumab treatment could increase
Demodex numbers in hair follicles, causing ocular rosacea-like dis-
ease.7 Ocular rosacea is a Th17-driven disease characterized by
an inflammatory cell infiltrate, mainly consisting of CD4+ T
cells, but not eosinophils.8 The unique combination of low con-
junctival GC numbers accompanied by numerous lymphocytes
and eosinophils found in this study may imply a new entity of
conjunctivitis in dupilumab-treated patients with AD.
Only patients with new onset of conjunctivitis symptoms or
worsened symptoms in cases of pre-existing conjunctivitis
were included in this study; these probably do not represent
all conjunctivitis cases during dupilumab treatment. In daily
practice, we experience some patients reporting improvement
of conjunctivitis symptoms during dupilumab treatment,
underlining the heterogeneity of the conjunctivitis.
Limitations of this study are small sample size, and collec-
tion of conjunctival biopsies at one single time point. There-
fore, dynamic differences in histopathological features before
and during dupilumab treatment could not be studied. Never-
theless, the histopathological features and findings were very
consistent, and constitute a first clue in the underlying path-
omechanism of dupilumab-associated conjunctivitis. However,
the exact pathomechanism of this new entity of conjunctivitis
could not be fully elucidated.
In conclusion, this study found a remarkable scarcity of con-
junctival GCs accompanied by an inflammatory T-cell- and eosi-
nophilic infiltrate in patients with AD with conjunctivitis during
dupilumab treatment. We hypothesize that the IL-13 blocking
effect of dupilumab might lead to reduction of GCs and mucin
production in a subpopulation of patients with AD, which may
potentially result in irritative conjunctivitis. A prospective study
further characterizing conjunctivitis in patients with AD before
and during dupilumab treatment will start soon.
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